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Which One Will Win In the Marketplace?*Blase Carabello, MDS ymptomatic aortic stenosis (AS) is a fatal diseaseunless treated by transcatheter aortic valvereplacement (TAVR). During the latter half of
the 20th century, aortic valve replacement (AVR) was
accomplished in the operating room using a variety
of replacement valves, both mechanical and bio-
prosthetic, the choice of which steadily evolved
over time. Bioprostheses avoid the need for vitamin
K antagonist anticoagulation (VKA) but are subject
to structural valve deterioration that occurs more
rapidly when they are implanted in younger versus
older patients (1). Mechanical prostheses are more
durable but require VKA and its attendant risks of
thromboembolism related to underanticoagulation
versus hemorrhage in cases of overanticoagulation.
It is fair to add that mechanical valves are not
entirely free of structural deterioration, and bio-
prostheses are not entirely free of thromboembo-
lism. However, irrespective of data that show
similar survival with mechanical and biologic valves
(2–4), most patients prefer to avoid the risks of
VKA, shifting their preference toward bioprostheses.
A bioprosthesis is also made more attractive by a
persistently decreasing risk of reoperation if
required for a failed valve and also by the unproven
but possible long-term strategy of inserting a valve
percutaneously inside a failed bioprosthesis, avoid-
ing reoperation. Pulmonary autografting (Ross pro-
cedure) offers the advantages of both durability in*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
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ever, this procedure is limited to surgeons who
have extensive experience in performing the opera-
tion. Ultimately, the type and make of the valve
implanted are based on patient and surgeon prefer-
ence. Although some patients focus on avoiding
reoperation, most prefer to avoid the risk of VKA
and the need for international normalized ratio
monitoring. Surgeon preference is usually predi-
cated on familiarity with a given make of valve,
its ease of implantation, and the implanting sur-
geon’s ultimate results with that valve.
ENTER TRANSCATHETER AVR
Describing TAVR as a game changer is an underesti-
mation. The ability to accomplish AVR without sur-
gery offers a life-saving device to inoperable patients
and to those at very high surgical risk; this technology
is still in its infancy (6,7). Progressive miniaturiza-
tion, valve designs that limit paravalvular leak (PVL)
(8), and devices that protect patients from cerebral
embolism (9) will almost surely facilitate the use of
TAVR in lower risk patients and facilitate enhanced
outcomes with lower complication rates. Durability
has been excellent in the typically elderly patient
undergoing TAVR. We are likely to learn more about
TAVR durability as TAVR indications become more
liberal, permitting implantation in younger patients
at lower surgical risk who will have a longer life
expectancy.
THE 3F ENABLE VALVE
In this issue of JACC: Cardiovascular Interventions, a
sutureless bioprosthesis the 3f Enable valve (Med-
tronic, Minneapolis, Minnesota) is compared with
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679TAVR using propensity matching (10). The 3f valve
(and other sutureless valves) should be more easily
implanted with shorter cross-clamp and cardiopul-
monary bypass times than conventional AVR.
Whether this would translate to a survival advantage
can only be established by a randomized trial. In the
current analysis, the sutureless valve had a substan-
tially higher risk of patient prosthetic mismatch
(perhaps) than TAVR, whereas TAVR had a higher
risk of PVL. (The latter point is probably moot
because new valve designs already have substantially
reduced PVL [8]).SEE PAGE 670The most dramatic ﬁnding in the current study
was a 17% reduction in stroke volume index (SVI)
for the patients implanted with the 3f valve after
surgery. Comparing groups without PVL (PVL com-
plicates calculation of forward SVI), the SVI differ-
ence was even more dramatic, 27% less in the 3f
valve patients. Even if this was not statistically
signiﬁcant, it would surely be clinically relevant.
This difference helps to account for the large in-
crease in patient-prosthesis mismatch and low ﬂow
in the 3f valve group.or does it? Stroke volume is
controlled by 3 properties: preload, afterload, and
contractility. Afterload should have been reduced
in both groups of patients after relief of outﬂow
obstruction, and, although there was a very slightly
greater post-operative gradient in the 3f valve
group, it is hard to imagine that a 2-mm Hg greater
gradient caused such a large decrease in SVI. This
assumption of reduced afterload would be vitiated
if there were a large number of untreated hyper-
tensive patients in the 3f valve group, in which
case, vascular load would be substituted for val-
vular load. But why would such a difference be
concentrated in 3f valve patients? Contractility
could have been impaired because of a lack of
myocardial protection during surgery, but the pre-
served ejection fraction (admittedly an awful guide
to contractility) was actually a bit higher in the 3f
valve group post-operatively. Could the 3f valve
group have been so volume contracted as to impair
SVI? It seems possible but very improbable. More
likely there was a systematic error in SVI measure-
ment. Because SVI is the product of outﬂow tract
area and the time-velocity integral, a systematic
undermeasurement of outﬂow tract area, perhaps
because of the nature of the valve, is the most
likely explanation for the ﬁnding of a reduced
calculated valve area and reduced SVI in the 3f
valve group.However, a truly greater risk of severe patient
prosthesis mismatch in the 3f valve group (instead
of an apparent one) would be an adverse ﬁnding
because the whole goal of AVR is to reduce obstruc-
tion of left ventricular outﬂow.
THE FUTURE OF THERAPY FOR AS
When the pathways leading to valve calciﬁcation are
better understood, pharmacological approaches to
prevent AS may become a reality but are currently a
long way off. For now, symptomatic AS is a lethal
mechanical obstruction of left ventricular outﬂow,
and for the foreseeable future, AVR will be the only
solution to the problem. TAVR is in its relative in-
fancy and will gain increased use as improvements in
valve design reduce risk and increase beneﬁt. How-
ever, there will almost certainly always be patients
who beneﬁt more from surgical AVR than from TAVR,
just as 37 years after the advent of percutaneous
coronary intervention (PCI), it is clear that many pa-
tients with obstructive coronary disease are better
treated with surgical bypass than with PCI. The sub-
stitute valves used in surgical AVR will also likely
evolve. It is likely that mechanical valves will always
require VKA for therapy, although a recent report
indicates success with a lower level of anti-
coagulation (11). Even so, these ﬁndings are unlikely
to completely reverse patient preference for valves
that do not require VKA. Of course, if a mechanical
valve were developed that required no VKA, the re-
sults might be different. In the meantime, bio-
prostheses that are dependable and easy to implant
will continue to prevail as the dominant choices for
AVR. Sutureless valves should offer a special advan-
tage in complex multivalve procedures in which
ischemic time becomes important and also may offer
an advantage in limited-access AVR. Whether these
advantages will translate into widespread use de-
pends on post-operative durability, hemodynamic
performance, and clinical outcomes determined by
randomized trials. In any case, the increased options
currently available can only help to beneﬁt the AS
patient of today compared with the few choices
available just a few decades ago. Hold onto your
hats—this is just the beginning of this revolution in
the treatment of heart valve disease!
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